Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

EntreMed Opens China Office

publication date: Mar 7, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
EntreMed, a Washington DC area biotech, has reacquired the China rights to its leading cancer drug candidate, ENMD-2076, and the company will open a China office to direct its work necessary for SFDA approval of the molecule. In 2010, EntreMed gave Selected Value Therapeutics a 16-month option on the China rights to ENMD-2076 as part of a $5.1 million funding. Now, following a $10 million capital raise from investors with China roots and the expiration of the prior deal, EntreMed is moving ahead on its own. More details....

Stock Symbol: (NSDQ: ENMD)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners